TOPICAL THERAPY FOR GENITAL HERPES

氧化还原制药公司的新型抗病毒和抗炎药物 有机金属化合物CTC 96(DoxovirTM)已显示出活性 在细胞培养和动物实验中抗单纯疱疹病毒(HSV)-1 人类眼病的模型。密切相关的HSV-2)，这是 在美国，每年数百万人和生殖器疱疹病例的原因将是 在动物模型中进行研究。在初步实验中，局部治疗 使用CTC 96导致原发病减少，并减少了 生殖道中的病毒，伴随着随后的减少 自发性复发。这种治疗后的长期影响 原发病与目前可用的抗病毒药物是无与伦比的。 以验证这些效应并调查治疗的部位 豚鼠生殖器疱疹和小鼠活动性模型的建立 将使用热再激活。CTC 96最佳浓度范围 关于治疗和预防的定义，以及CTC 96对 重新激活的潜伏病毒的潜伏期和复制的建立将 要下定决心。Redox打算寻求IND批准进行测试 生殖器疱疹临床试验中局部应用CTC 96为目标 第二阶段的SBIR应用程序。 拟议的商业应用：这项研究将阐明潜在的 使用Redox的抗疱疹药物(CTC 96；DoxovirTM)治疗和 预防初级生殖器疱疹和复发性感染。确实有 美国每年约有70万例初发病例和2000万例复发 独自一人。全球领先的解热药年销售量， 阿昔洛韦，超过10亿美元。DoxovirTM还可以用于 口腔面部疱疹(每年约5000万例)和其他皮肤疱疹 感染(如带状疱疹)。潜在市场包括传染病 世界各地的专家、皮肤科医生和全科医生及其 病人。

Redox Pharmaceutical Corporation's new antiviral and anti-inflammatory organometallic compound, CTC 96 (DoxovirTM) has demonstrated activity against herpes simplex virus (HSV) type-1 in cell culture and animal models of human ocular disease. The closely related HSV-2), which is the cause of millions and cases of genital herpes each year in the US, will be studied in animal models. In preliminary experiments, topical therapy with CTC 96 resulted in a reduced incidence of primary disease and reduced virus in the genital tract, accompanied by a reduction of subsequent spontaneous recurrence. This long-lasting effect following treatment of primary disease is unparalleled with currently available antiviral drugs. To verify these effects and to investigate the locus of therapeutic activity, established models of guinea pig genital herpes and mouse thermal reactivation will be used. Optimal CTC 96 concentration ranges for therapy and prophylaxis will be defined, and CTC 96 influence on the establishment of latency and replication of reactivated latent virus will be determined. Redox intends to pursue IND approval for testing of topical CTC 96 in human clinical trials of genital herpes as an objective of a Phase II SBIR application. PROPOSED COMMERCIAL APPLICATION: This research will clarify the potential use of Redox's antiherpetic agent (CTC 96; DoxovirTM) for therapy and prevention of primary genital herpes and recurrent infections. There are about 700,000 primary cases and 20 million recurrences annually in the US alone. Yearly worldwide sales of th leading antitherpetic drug, acyclovir, exceed $1 billion. DoxovirTM could also be useful for orofacial herpes (about 50,000,000 cases per year) and other dermal herpes infections (e.g., shingles). Potential markets include infectious disease specialists, dermatologists and general practitioners world-wide and their patients.